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Background:Women prescribed antipsychotics face the dilemmaonwhether to continuemedication in pregnan-
cy in terms of balancing risks and beneﬁts. Previous research on other psychotropic medications suggests that
many women discontinue treatment in early pregnancy. However, very limited evidence exists on discontinua-
tion of antipsychotic medication.
Methods:We identiﬁed 495,953 pregnant women from THIN primary care database. Kaplan–Meier plots were
used to examine time to last antipsychotic prescription. Poisson regression was used to examine characteristics
of those who stopped treatment during pregnancy.
Results: There has been an overall increase in prevalence of antipsychotic prescribing since 2007. However,
antipsychotics were more likely to be stopped in pregnant than non-pregnant women. Only 107/279 (38%) of
women on atypical antipsychotics and 39/207 (19%) of women on typical antipsychotics before pregnancy
still received treatment at the start of third trimester. Olderwomenweremore likely to continue typical antipsy-
chotic treatment in pregnancy (35+ versus b25 years risk ratio: 3.09 [95% CI 1.76, 5.44]). Likewise, those who
received typical antipsychotics for longer periods before were most likely to continue treatment in pregnancy
(12+ versus b6 months: RR: 3.12 [95% CI 1.97, 4.95]). For atypical antipsychotics length and dose of prior pre-
scribing were also associated with continuation in pregnancy.
Conclusions: Pregnancy was a major determinant of cessation of antipsychotics. Only 38% of women on atypical
and 19% on typical antipsychotics were still prescribed the drug in the third trimester. Duration of prior treat-
ment, maternal age as well as dose was signiﬁcantly associated with continued treatment of antipsychotics in
pregnancy.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The onset of schizophrenia and bipolar disorder in women usually
occurs within childbearing age (Yonkers et al., 2004; Einarson and
Boskovic, 2009; Hardoon et al., 2013) and many women with these ill-
nesses are prescribed psychotropic medication including antipsychotics
(Einarson and Boskovic, 2009; Hayes et al., 2011; Prah et al., 2012).
Some women are prescribed antipsychotics either before they get a di-
agnosis of refractory mood and anxiety disorders. Women prescribed
antipsychotics face the dilemma at the time of pregnancy or when
planning a pregnancy on whether to continue psychotropic medication
in terms of balancing the potential teratogenic effects and other adverse
effects of the medication against the consequences of a relapse of their
illness (Galbally et al., 2011). However, limited information is available
on the risks and beneﬁts of antipsychotic treatment in pregnancy
(Einarson and Boskovic, 2009).
Webb et al. conducted a systematic review in 2004 (updated in
2009) to establish whether the beneﬁts of taking antipsychotic drugs
outweigh the risks for pregnant or postpartum women and found no
randomised controlled trials (Webb et al., 2004). A Swedish population
registry study identiﬁed 570 women being prescribed antipsychotics in
pregnancy and found that thiswas associatedwith increased risk of ges-
tational diabetes (OR 1.78 95% CI 1.04–3.01) (Reis andKällén, 2008) and
congenital malformations (OR 1.52 (95% CI 1.05–2.19)) in comparison
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to women not prescribed antipsychotics. This association was not spe-
ciﬁc to certain drugs suggesting that the underlying pathology or un-
identiﬁed confounding could explain the excess risk of congenital
malformations (Reis and Källén, 2008). A recent Canadian study
assessed 133 pregnant women exposed to second generation antipsy-
chotics against healthy women (Sadowski et al., 2013). Exposed neo-
nates were more likely to be born prematurely and had higher rates of
congenital malformations and this was particularly the case for those
subject to poly-therapy (atypical antipsychotics aswell as other psycho-
tropic medication). In this study a relatively high proportion (72%) of
women were on poly-therapy and 101/133 (76%) continued treatment
throughout pregnancy (Sadowski et al., 2013).
Advice on treatment varies across countries and in some places
standard psychiatric advice is that women maintain pharmacological
treatment across the perinatal period (Galbally et al., 2011). The
National Institute for Health and Clinical Excellence (NICE) guideline
on antenatal and postnatalmental health raises speciﬁc issueswith cer-
tain antipsychotics, but does not provide general recommendations on
whether to stop or continue antipsychotic treatment in this period
(National Institute for Health and Clinical Excellence, 2007). Previous
research on other psychotropic medications including antidepressants
and antiepileptic drugs suggests that many women discontinue treat-
ment in early pregnancy (Petersen et al., 2011; Man et al., 2012). How-
ever, very limited evidence exists on extent of antipsychotic prescribing
in pregnancy andwhether pregnancy is associatedwith discontinuation
of antipsychotic medication.
We investigated prescribing of antipsychotic medication in the
United Kingdom primary care before and during pregnancy using data
from The Health Improvement Network (THIN), a large primary care
database. The aim of our study was to examine whether pregnancy
was a determinant for discontinuation of antipsychotics and if so, to
identify factors associated with discontinuation.
2. Methods
2.1. Data source
Weuseddata fromTheHealth ImprovementNetwork (THIN) primary
care database (http://csdmruk.cegedim.com/), one of the largest primary
care databases that provide longitudinal health records. The database cur-
rently holds data from 578 practices and is approximately representative
of the United Kingdom population (Blak et al., 2011). Over 98% of the UK
population are registered with a general practitioner (family doctor)
(Lis andMann, 1995). Diagnoses and symptoms are recorded by practice
staff using Read codes, a hierarchical coding system (Chisholm, 1990). In
addition, THIN holds individual patient level information about year of
birth, date of registration, and death or transfer out of the practice. Social
deprivation is recorded for each individual by quintiles of Townsend
scores, which is based on information from the 2001 census.
While antenatal care is often shared between general practice
staff and midwives, the general practitioner remains responsible for
women's general medical care during pregnancy including prescribing
of medicines. Some women with psychosis also receive care from local
National Health Service (NHS) mental health trusts, but most mental
health trusts have limited prescribing budgets and for most women
the continuing prescription of psychotropic medication will still remain
with the general practitioners.
2.2. Participants
We identiﬁedwomenwhowere permanently registered with one of
the general practices that contributed data to THIN for the period be-
tween 1 January 1995 and 31 December 2012 for at least six months be-
fore the pregnancy and throughout their pregnancy. We included
women who received continuous antipsychotic medication before they
becamepregnant i.e. womenwere selected if they received prescriptions
between 6 and 4 months (inclusive) before they became pregnant and
received at least one further prescription in the three months before
the start of pregnancy. Thus, we focused on women who received two
or more prescriptions of antipsychotics in the six months leading up to
pregnancy. In accordance with clinical practice in the United Kingdom,
the ﬁrst day of the last menstrual period was considered as the start of
pregnancy. The duration of the pregnancy was estimated from informa-
tion on the date of the last menstrual period, antenatal records, delivery
information, dates of postnatal examinations and gestational age at
birth. Pregnancies that ended in miscarriage or termination were not
included in the study. We conducted separate analyses for women in
receipt of typical and atypical antipsychotics prior to pregnancy and for
each of these groups we identiﬁed comparison groups of twice as
many women also in receipt of antipsychotic prescriptions, but not
being pregnant for at least 12 months before and 24 months after a
randomly selected index date. We stratiﬁed this group such that the
age distribution was similar in the pregnant and non-pregnant sample.
A few women treated with antipsychotics (n = 19) had records of
more than one eligible pregnancy; in these situations we randomly
selected one of the pregnancies.
Antipsychotic prescribing wasmost commonly prescribed atmonthly
intervals, although there was substantial variation. Therefore, we consid-
ered women to have discontinued antipsychotic medication if they had
received no further prescriptions after three months.
We also calculated the average daily dose of antipsychotic medica-
tion during the period from six to four months before the start of preg-
nancy by dividing the total mass of drug prescribed over the period by
the expected total duration of the relevant prescriptions. Durations
were estimated with the help of the Enhanced Dosage Determination
method developed by the University of Nottingham Division of Epide-
miology and Public Health (Gibson, 2012). The mass of each antipsy-
chotic drug was standardised into units of the Deﬁned Daily Dose
(DDD) for maintenance treatment of psychosis (WHO Collaborating
Centre for Drug Statistics Methodology, 2013).
2.3. Data analysis
2.3.1. Secular trends
We estimated annual prevalence of antipsychotic prescribing before
and during pregnancy for every two calendar years between 1995 and
2012, stratiﬁed by typical and atypical antipsychotics. Subsequently,
we followed pregnant and non-pregnant women who were prescribed
antipsychotics from 3 months before the pregnancy (or the index date
for the non-pregnant women) and identiﬁed when they had their last
consecutive prescription. We ended the follow-up after 220 days (two
months before delivery). In the case of a premature delivery earlier
than 220 days, follow-up was terminated at delivery. Although we de-
ﬁned stopping of antipsychotics as the date of issue of the last prescrip-
tion, some women would continue taking the drug beyond this point.
2.3.2. Factors determining continuation of antipsychotic prescribing in
pregnant women
For pregnant women we further examined whether continuation of
antipsychotic prescribing beyond six weeks of pregnancy was associat-
ed with age, the average daily dosage, length of time the antipsychotic
had been prescribed prior to pregnancy, prescription of antidepressants
and/or mood stabilisers, records of illicit drug or alcohol problems, obe-
sity, parity, social deprivation and ethnicity using a Poisson regression
model with robust variance estimates to account for clustering within
general practice. We estimated the univariate relative risk ratios for
each of the variables as well as relative risk ratios adjusted for age and
average daily dose.
Many factors may impact the decisions to continue or discontinue
antipsychotic medication in pregnancy. However, we chose to examine
the variables described above as they were available from primary care
electronic health records. While there is no direct measurement of
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severity of illness the average daily dosage and length of time the anti-
psychotic had been prescribed prior to pregnancy may be indicative of
the severity of illness.
2.4. Ethics
The scheme for THIN to obtain and provide anonymous patient data
to researchers was approved by the National Health Service South-East
Multicenter Research Ethics Committee (MREC) in 2002 and scientiﬁc
approval for this study was obtained from CSD Medical Research's
Scientiﬁc Review Committee.
3. Results
Overall, we identiﬁed 495,953 pregnancies in 365,138 women. Of
these pregnancies, we identiﬁed 1442 (0.29%) in which women were
prescribed antipsychotics in the six months before they became preg-
nant and 945 (0.19%) in which women were prescribed antipsychotics
after the pregnancy was likely to be known (after six weeks). The over-
all annual prevalence of prescribing of antipsychotics before and in
pregnancywas relatively constant between 1995 and 2007 (Fig. 1). Pre-
scribing of typical antipsychotics has been declining since 1998, while
prescribing of atypical antipsychotics has been increasing, resulting in
an overall increase since 2007 in prescribing of antipsychotics both be-
fore and during pregnancy (Fig. 1).
3.1. Discontinuation of antipsychotic prescription in pregnancy
We identiﬁed 207 women receiving typical antipsychotics and 279
receiving atypical antipsychotics in the six to four months before they
became pregnant and at least one further prescription within the fol-
lowing three months.
Pregnant and non-pregnant women prescribed atypical antipsy-
chotics discontinued at similar rates up to the start of pregnancy
(or index date) (Fig. 2). However, after six weeks of pregnancy (when
the woman is likely to become aware of the pregnancy) only 150/279
(54%) of the women received further prescriptions and by the start of
the third trimester this ﬁgure was reduced to 107/279 (38%) (Fig. 2).
For women on typical antipsychotics there was a substantial difference
in the rates of discontinuation between pregnant and non-pregnant
women even before the pregnancy (Fig. 2). By six weeks of pregnancy
only 73/207 (35%) received further prescriptions thereafter and by the
start of the third trimester it was down to 39/207 (19%) (Fig. 2).
The rates of discontinuation differed by dose and type of antipsy-
chotics (Fig. 3).Women prescribed lower doses were least likely to con-
tinue treatment in pregnancy. Amongwomen receiving prescriptions of
less than 0.25 of the deﬁned daily dose (DDD) of typical antipsychotics,
only 29/118 (25%) continued prescriptions after six weeks. For women
on atypical antipsychotics the ﬁgure was 24/52 (46%) after six weeks
(Fig. 2). The comparisonswith non-pregnant women, however, suggest
that awareness of the pregnancy may not be the only reason for
Fig. 1. Trends in prevalence of prescribing of antipsychotics before (upper graph) and during pregnancy (lower graph).
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stopping antipsychotics. About 25% of non-pregnant women stopped
both typical and atypical antipsychotics over the same time period as
the pregnant women.Women on a high dose (DDD N 1) of typical anti-
psychotics were highly likely to discontinue prescriptions prior to preg-
nancy in contrast to women on a high dose (DDD N 1) of atypical
antipsychotics (Fig. 3). Three out of ﬁfteen women on high dose typical
antipsychotics were on depots.
Factors associated with continuation of receiving antipsychotic pre-
scriptions beyond six weeks of pregnancy for typical antipsychotics in-
cluded age and durations of treatment prior to pregnancy (Table 1).
Those aged 35 years or above were more than three times as likely to
continue treatment compared to those below 25 years (RR: 3.09 [95%
CI 1.76,5.44] (Table 1)). The effect of age attenuated slightly after adjust-
ment for dose (Table 1). Likewise, those who had received continuous
treatment for more than 12 months prior to pregnancy were also
more likely to continue treatment in pregnancy compared to those
who had received less than 6 months of continuous treatment prior to
pregnancy (RR: 3.12 [95% CI 1.97, 4.95] (Table 1)). This was still the
case after adjustment for age and dose (RR: 2.48 [95% CI 1.54, 3.99]
(Table 1)). For atypical antipsychotics length and dose of prior prescrib-
ing were also associated with continuation in pregnancy (Table 2).
However, those aged 30–34 years were themost likely to continue pre-
scriptions in pregnancy (Table 2). For other factors examined (diagnosis
of severe mental illnesses, also taking antidepressants and mood
stabilisers, social deprivation, estimated parity, obesity, smoking,
records of alcohol problems, illicit drug use and ethnicity) none of
the adjusted effect sizes were larger than 1.65 or lower than 0.64
(Tables 1 and 2).
In general, few women switched between typical and atypical anti-
psychotic treatment just before or in pregnancy. Only 5/207 (2.4%)
0.00
0.25
0.50
0.75
1.00
207 117 73 50 39Pregnant
414 333 312 285 245Non-pregnant
Number at risk
3 months before start Start 6 weeks 2nd trimester 3rd trimester
Non-pregnant women
Pregnant women
Typical antipsychotics
0.00
0.25
0.50
0.75
1.00
279 212 150 122 107Pregnant
558 475 450 420 379Non-pregnant
Number at risk
3 months before start Start 6 weeks 2nd trimester 3rd trimester
Atypical antipsychotics
Fig. 2. Discontinuation of antipsychotic drugs in pregnant and non-pregnant women, by a) typical and b) atypical antipsychotics.
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women switched from typical to atypical antipsychotics and 9/279
(3.2%) switched from atypical to typical antipsychotics. However,
among the more frequently used antipsychotics, switching levels were
high for a couple of drugs: 12/50 women (24.0%) switched from risper-
idone to another antipsychotic, while 9/48 (18.8%) switched from tri-
ﬂuoperazine to another antipsychotic.
4. Discussion
The overall prescribing of antipsychotics in pregnancy has been rel-
atively constant up to 2007 although there seems to be an increase in
the last few years due to more women being prescribed atypical anti-
psychotics. Many women were not prescribed further antipsychotics
after sixweeks of pregnancy suggesting that pregnancy is amajor deter-
minant for stopping antipsychotic prescribing. Thosemost likely to con-
tinue treatmentwere thosewho had received continuous treatment for
more than 12 months prior to pregnancy. Other determinants for con-
tinuation of antipsychotic prescribing in pregnancy included women's
age and being on higher pre-pregnancy treatment doses.
As primary care databases do not have information on dispensing or
compliance, we cannot be sure that women actually took the prescribed
antipsychotics and we won't have the exact date women may have
stopped their medication. However, by including women who received
repeat prescriptions prior to pregnancy it is more likely that they were
using themedication compared to those who just received a single pre-
scription. As outlined in the Methods section, the primary prescribing
budget is with the NHS primary care trusts and hence it is likely that
we have captured most antipsychotic prescriptions issued during preg-
nancy. However, inpatient prescriptions and some specialist medica-
tions prescribed in secondary care, such as clozapine, will not have
been captured by primary care databases. Although, we expect this
would have been the case for a very small minority of the women. The
0.00
0.25
0.50
0.75
1.00
118 59 29 15 13  <0.25 DDD
74 53 39 32 23  0.25-1 DDD  
15 5 5 3 3  >1 DDD
Number receiving drug:
3 months before start Start 6 weeks 2nd trimester 3rd trimester
>1 DDD
0.25-1 DDD
<0.25 DDD
Typical antipsychotics
0.00
0.25
0.50
0.75
1.00
52 43 24 15 13  <0.25 DDD
151 105 73 62 53  0.25-1 DDD  
76 64 53 45 41  >1 DDD
Number receiving drug:
3 months before start Start 6 weeks 2nd trimester 3rd trimester
Atypical antipsychotics
Fig. 3. Discontinuation of antipsychotic drugs in pregnant women, by dose in women who were prescribed a) typical and b) atypical antipsychotics.
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strength of our study is that the database covers real time clinical prac-
tice and the prospective nature of studywouldmake it not subject to re-
call biases.
Other studies have found an increase in atypical antipsychotic pre-
scription in pregnancy over the last decades (Epstein et al., 2013; Toh
et al., 2013). However, to our knowledge, this is the ﬁrst study to exam-
ine in detail the patterns of antipsychotic prescribing in pregnancy and
the level of discontinuation during gestation. It appears that knowledge
of pregnancy was a major reason for stopping antipsychotics. A large
proportion of the women who received their last prescription within
the ﬁrst six weeks of gestation may not be aware of the pregnancy. By
the time the prescription would be due for renewal many women
would have been aware of their pregnancy and have decided to stop
the medication. The general practitioner as well as the pregnant
woman's mental health team/consultant may play a pivotal role in ad-
vising an individual woman on continuation of prescribed medicines
in pregnancy. This would be in keeping with the recommendations
made by national formularies and the NICE guidelines (National
Institute for Health and Clinical Excellence, 2006, 2007). Since the rec-
ommendations are often non-speciﬁc, both health care professionals
and the women are left with a very difﬁcult and complex decision. In
each individual case they have to weigh up risks to the mother and
child of continuation versus discontinuation of medication in the ab-
sence of clear evidence. This is the ﬁrst study to examine discontinua-
tion of antipsychotic prescribing in pregnancy based on the UK
primary care data. However, further research is needed in other settings
to examinewhether the background and training of the health care pro-
fessionals may impact the decision process.
The greatest risk of discontinuation of the antipsychotic medication
is the possibility of relapse of the mental illness in pregnancy and post-
partum. An observational study of mood disorders in 2252 pregnancies
and postpartum periods demonstrated that women with bipolar
Table 1
Factors associated with receiving typical antipsychotics prescriptions beyond 6 weeks after the estimated pregnancy start date. Results of Poisson regression (using robust variance
estimation).
n Typical antipsychotics (n = 207)
Unadjusted Adjusted
RR 95% CI p value RR 95% CI p value
Average daily dose (in units of DDD) b0.001 0.011
b0.25 DDD 118 1 1
0.25–1 DDD 74 2.14 [1.46,3.15] 1.78 [1.22,2.60]
N1 DDD 15 1.36 [0.62,2.97] 1.25 [0.58,2.68]
Age band b0.001 b0.001
b25 53 1 1
25–29 42 1.49 [0.74,2.99] 1.34 [0.68,2.62]
30–34 59 1.22 [0.62,2.43] 1.15 [0.58,2.29]
35+ 53 3.09 [1.76,5.44] 2.60 [1.47,4.59]
Continuous prior time on antipsychotics b0.001 0.001
b6 months 98 1 1
6–12 months 34 1.92 [1.03,3.57] 1.78 [0.97,3.26]
N12 months 75 3.12 [1.97,4.95] 2.48 [1.54,3.99]
SMI diagnosis code 0.018 0.404
No 160 1 1
SMI diagnosis code 47 1.57 [1.08,2.27] 1.17 [0.81,1.71]
Also taking an antidepressant 0.238 0.566
No 66 1 1
Taking an antidepressant 141 0.80 [0.55,1.16] 0.90 [0.64,1.28]
Also taking a mood stabiliser 0.033 0.281
No 191 1 1
Taking a mood stabiliser 16 1.68 [1.04,2.71] 1.31 [0.80,2.12]
Townsend quintile 0.562 0.440
1 16 1 1
2 22 0.85 [0.35,2.05] 0.72 [0.32,1.61]
3 36 0.67 [0.28,1.56] 0.64 [0.29,1.43]
4 61 1.14 [0.57,2.28] 1.07 [0.57,1.99]
5 68 0.98 [0.48,1.99] 0.89 [0.47,1.68]
Unrecorded 4
Estimated parity 0.103 0.159
0 84 1 1
1 57 1.47 [0.91,2.40] 1.34 [0.87,2.08]
2 44 1.82 [1.13,2.93] 1.65 [1.06,2.57]
3 or more 22 1.39 [0.72,2.69] 1.52 [0.80,2.90]
Obesity status 0.771 0.759
Not obese 186 1 1
Obese 21 1.09 [0.61,1.95] 1.09 [0.63,1.90]
Smoking status 0.912 0.602
Non-smoker 106 1 1
Smoker 101 1.02 [0.71,1.48] 1.09 [0.78,1.53]
Alcohol problems 0.154 0.094
No 191 1 1
Yes 16 1.47 [0.87,2.50] 1.59 [0.92,2.75]
Illicit drug use 0.941 0.866
No 181 1 1
Yes 26 0.98 [0.56,1.72] 1.05 [0.60,1.84]
Ethnicity
Other 204 1 1
Black or minority ethnic 3 Could not be estimated—all 3 continue receiving prescriptions
Adjustment variables: dose and age band.
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disorders were at particularly high risk of developing major depression
in the postpartum period (prevalence: 19% and 29% in women with bi-
polar I disorder and bipolar II disorder, respectively) (Viguera et al.,
2011). Likewise, it has been shown that women with a history of psy-
chotic disorder were at higher risk of postpartum psychiatric illness, in
particular non-psychotic anxiety and depressive disorders (Howard
et al., 2004). Case-reports of suicide among these women highlight the
severity of these illnesses (Jones, 2005). Aside from the direct effects
of discontinuation of psychotropic medication on the mother, the indi-
rect impact on the foetus and child of severe depression and puerperal
psychosis also need to be taken into consideration. Yet we observed a
large proportion of women discontinuing antipsychotics in pregnancy
—similar to the trends observed for pregnant women on antidepres-
sants and women treated with antiepileptic drugs for bipolar disorder
(Petersen et al., 2011; Man et al., 2012). Women may have different
reasons to discontinue, some may discontinue as they fear the antipsy-
choticmedicationwill harm the unborn child andweigh that uncertain-
ty of risk higher than the potential risk of relapse. Other women may
discontinue antipsychotics in this period because they may no longer
need the medication. We also observed that a number of women on
high dose typical antipsychotics ceased prescribing before they became
pregnant, including three women on depots. This may be a part of
pregnancy planning, but could also be explained by the fact that
typical antipsychotics are known to reduce fertility by inducing
hyperprolactinaemia. Finally, the comparison of discontinuation be-
tween non-pregnant and pregnant women revealed that pregnancy is
not the only reason forwomen to discontinue antipsychoticmedication.
Other factors such as experience of adverse effects and stigmatisation
associated with antipsychotics may inﬂuence continuous prescribing
in pregnant as well as non-pregnant women.
Table 2
Factors associated with receiving atypical antipsychotic prescriptions beyond 6 weeks after the estimated pregnancy start date. Results of Poisson regression (using robust variance
estimation).
n Atypical antipsychotics (n = 279)
Unadjusted Adjusted
RR 95% CI p value RR 95% CI p value
Average daily dose (in units of DDD) 0.002 0.003
b0.25 DDD 52 1 1
0.25–1 DDD 151 1.05 [0.75,1.47] 1.04 [0.74,1.47]
N1 DDD 76 1.51 [1.09,2.10] 1.48 [1.06,2.07]
Age band 0.147 0.201
b25 53 1 1
25–29 74 1.24 [0.84,1.83] 1.23 [0.84,1.80]
30–34 82 1.50 [1.04,2.15] 1.45 [1.02,2.08]
35+ 70 1.34 [0.92,1.97] 1.31 [0.90,1.92]
Continuous prior time on antipsychotics b0.001 0.001
b6 months 100 1 1
6–12 months 53 1.34 [0.93,1.93] 1.34 [0.93,1.94]
N12 months 126 1.78 [1.34,2.35] 1.67 [1.27,2.21]
SMI diagnosis code 0.005 0.073
No 136 1 1
SMI diagnosis code 143 1.39 [1.11,1.74] 1.25 [0.98,1.59]
Also taking an antidepressant 0.097 0.402
No 96 1 1
Taking an antidepressant 183 0.83 [0.67,1.03] 0.91 [0.73,1.13]
Also taking a mood stabiliser 0.098 0.574
No 232 1 1
Taking a mood stabiliser 47 1.23 [0.96,1.58] 1.08 [0.83,1.40]
Townsend quintile 0.880 0.805
1 26 1 1
2 32 1.10 [0.70,1.74] 1.07 [0.68,1.67]
3 52 0.93 [0.59,1.45] 0.87 [0.56,1.35]
4 72 0.93 [0.61,1.42] 0.87 [0.57,1.33]
5 85 1.03 [0.69,1.54] 0.94 [0.63,1.41]
Unrecorded 12
Estimated parity 0.474 0.511
0 110 1 1
1 89 0.89 [0.70,1.15] 0.92 [0.72,1.18]
2 49 0.79 [0.57,1.11] 0.82 [0.58,1.14]
3 or more 31 0.82 [0.55,1.22] 0.80 [0.54,1.18]
Obesity status 0.055 0.119
Not obese 223 1 1
Obese 56 1.26 [1.00,1.59] 1.21 [0.95,1.53]
Smoking status 0.875 0.935
Non-smoker 142 1 1
Smoker 137 0.98 [0.79,1.22] 0.99 [0.80,1.23]
Alcohol problems 0.595 0.385
No 264 1 1
Yes 15 1.12 [0.73,1.73] 1.22 [0.78,1.90]
Illicit drug use 0.370 0.340
No 246 1 1
Yes 33 1.15 [0.85,1.55] 1.16 [0.85,1.58]
Ethnicity 0.087 0.214
Other 249 1 1
Black or minority ethnic 30 1.28 [0.97,1.69] 1.20 [0.90,1.59]
Adjustment variables: dose and age band.
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5. Conclusion
Overall, prescription rates for antipsychotics in pregnancy have been
relatively stable over the last two decades. Prescribing of atypical antipsy-
chotics has been increasing both before and during pregnancy, resulting
in a slight increase in overall prevalence of prescribing since 2007.
However, pregnancy is strongly associated with women discontinuing
antipsychotic medication. Less than 40% of womenwho received atypical
antipsychotics prior to pregnancy were still in receipt of them at the start
of their third trimester. For typical antipsychotics the ﬁgure was down to
19% by the start of third trimester. Duration of prior treatment, maternal
age aswell as dosewas signiﬁcantly associatedwith continued treatment
of antipsychotics in pregnancy.
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